2026: The Year Weight Loss Pills Transform the $150 Billion Obesity Market
Eli Lilly's orforglipron and Novo Nordisk's oral semaglutide are poised for FDA approval in 2026, potentially bringing GLP-1 weight loss treatment to millions who avoid injections.